MAINTENANCE THERAPY OF A PARP INHIBITOR IN TREATING GASTRIC CANCER
Disclosed herein is a method for maintenance therapy of a PARP inhibitor in treating a subject with gastric cancer (GC) comprising administering to the subject a therapeutic or maintenance effective amount of a PARP inhibitor, wherein the subject had previously received chemotherapy.
1 . A method for providing maintenance therapy in a subject with gastric cancer comprising administering to the subject a therapeutic or maintenance effective amount of a PARP inhibitor, wherein the subject had previously received chemotherapy.
2 . The method of claim 1 , wherein the subject is initially diagnosed with advanced or metastatic gastric cancer.
3 . The method of claim 2 , wherein the subject is initially diagnosed with inoperable locally advanced or metastatic gastric cancer.
4 . The method of claim 1 , wherein the gastric cancer is adenocarcinoma of the stomach or gastroesophageal junction with inoperable locally advance or metastatic disease.
5 . The method of claim 1 , wherein the subject has previously received platinum-based chemotherapy.
6 . The method of the claim 5 , wherein the subject has previously received first line platinum-based chemotherapy.
7 . The method of any one of claim 6 , wherein the subject has previously received platinum-based chemotherapy in combination with fluoropyrimidine-based therapy.
8 . The method of claim 7 , wherein the subject received cisplatin, oxaliplatin, or carboplatin as the platinum-based chemotherapy.
9 . The method of claim 8 , wherein the subject had a complete response (CR) or a partial response (PR) to the previous platinum-based chemotherapy before the initiation of the maintenance therapy.
10 . The method of claim 9 , wherein the gastric cancer expresses high level of homologous recombination deficiency (HRD).
11 . The method of claim 10 , wherein the gastric cancer has one or more of the mutant genes involved in HRD, selected from the group consisting of BRCA1/2, BRCA-like genomic scarring, RAD51, PALB2, ATR, and ATM.
12 . The method of claim 1 , wherein the PARP inhibitor is olaparib, niraparib, rucaparib or pamiparib.
13 . The method of claim 1 , wherein the PARP inhibitor is pamiparib.
14 . The method of claim 13 , wherein pamiparib is administered at a dose of 60 mg BID.